Multimedix Limited

	Page
Balance Sheet	1—2
Notes to the Financial Statements	3—6

Registered number: 13888591

		2026		2025
	Notes	£	£	£	£
FIXED ASSETS
Intangible Assets	4		6,818		7,892
Tangible Assets	5		17,348		13,463

			24,166		21,355
CURRENT ASSETS
Debtors	6	58,200		2,022
Cash at bank and in hand		7,568		32,235

		65,768		34,257
Creditors: Amounts Falling Due Within One Year	7	(157,410 )		(95,502 )

NET CURRENT ASSETS (LIABILITIES)			(91,642 )		(61,245 )

TOTAL ASSETS LESS CURRENT LIABILITIES			(67,476 )		(39,890 )

NET LIABILITIES			(67,476 )		(39,890 )

CAPITAL AND RESERVES
Called up share capital	8		100		100
Profit and Loss Account			(67,576 )		(39,990 )

SHAREHOLDERS' FUNDS			(67,476)		(39,890)

Page 1

Page 2

Multimedix Limited

Balance Sheet (continued)

As At 31 March 2026

For the year ending 31 March 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.

On behalf of the board

M A Stevenson

Director

22 September 2026

The notes on pages 3 to 6 form part of these financial statements.

1. General Information

Multimedix Limited is a private company, limited by shares, incorporated in England & Wales, registered number 13888591 . The registered office is Pera Business Park, Nottingham Road, Melton Mowbray, LE13 0PB.

2. Accounting Policies

2.1. Basis of Preparation of Financial Statements

The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

2.2. Going Concern Disclosure

The company’s financial statements have been prepared on a going concern basis on the grounds that current and future sources of funding or support will be more than adequate for the company’s needs.

The business has diversified its risk by offering Quality Assurance (QA) checks with a growing number of long term contracts alongside its R&D work. Ultrasound is a growing imaging modality driven by the rising interest in portable ultrasound in particular, necessitating annual QA checks. Cashflow is monitored regularly with the parent company offering short term financial support. The parent company has agreed to support the company for the forseeable future.

Based on the above and in assessing going concern, the director has a reasonable expectation that the company will continue as a going concern and is able to meet all of its obligations as they fall due for a minimum of 12 months from the date of approval of these financial statements.

2.3. Turnover

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.

Rendering of services

Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.

2.4. Intangible Fixed Assets and Amortisation - Intellectual Property

Intellectual property assets are costs of patents.

Patents are initially measures at cost. After intial recognition, patents are measure at cost less any accumulated amortisation and any accumulated impairment losses.

They are amortised to the profit and loss account over their estimated economic life of 10 years.

2.5. Tangible Fixed Assets and Depreciation

Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Plant & Machinery	20% straight line
Fixtures & Fittings	20% straight line
Computer Equipment	20% straight line

Page 3

Page 4

Multimedix Limited

Notes to the Financial Statements (continued)

For The Year Ended 31 March 2026

2.6. Financial Instruments

Trade and other debtors / creditors

Trade and other debtors are recognised initially at transaction prices less attributable transaction costs. Trade and other creditors are recognised initially at transaction price plus attributable transaction costs. Subsequent to initial recognition they are measured at amortised cost using the effective interest method, less any impairment losses in the case of trade debtors. If the arrangement constitutes a financing transaction, for example if payment is deferred beyond normal business terms, then it is measured at the present value of future payments discounted at a market rate of interest for a similar debt instrument.

Impairment of financial assets

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found an impairment loss is recognised within profit or loss.

For financial assets that are measured at amortised cost, the impairment loss is measured as the difference between the asset’s carrying amount and the present value of estimated cash flows discounted at the asset’s original effective interest rate.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between the asset’s carrying amount and the best estimate of the amount that the company would receive for the asset if it were to be sold at the balance sheet date.

2.7. Foreign Currencies

Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.

2.8. Pensions

The company operates a defined pension contribution scheme. Contributions are charged to the profit and loss account as they become payable in accordance with the rules of the scheme.

2.9. Related party exemption

The company has taken advantage of the exemption available under FRS 102 not to disclose related party transactions with wholly owned subsidiaries in the group.

3. Average Number of Employees

Average number of employees, including directors, during the year was as follows: 7 (2025: 6)

4. Intangible Assets

	Trademarks & patents
	£
Cost
As at 1 April 2025	10,741

As at 31 March 2026	10,741

Amortisation
As at 1 April 2025	2,849
Provided during the period	1,074

As at 31 March 2026	3,923

Net Book Value
As at 31 March 2026	6,818

As at 1 April 2025	7,892

Page 4

Page 5

Multimedix Limited

Notes to the Financial Statements (continued)

For The Year Ended 31 March 2026

5. Tangible Assets

	Plant & Machinery	Fixtures & Fittings	Computer Equipment	Total
	£	£	£	£
Cost
As at 1 April 2025	14,807	1,599	6,254	22,660
Additions	10,538	-	-	10,538

As at 31 March 2026	25,345	1,599	6,254	33,198

Depreciation
As at 1 April 2025	5,766	940	2,491	9,197
Provided during the period	5,083	319	1,251	6,653

As at 31 March 2026	10,849	1,259	3,742	15,850

Net Book Value
As at 31 March 2026	14,496	340	2,512	17,348

As at 1 April 2025	9,041	659	3,763	13,463

6. Debtors

	2026	2025
	£	£
Due within one year
Trade debtors	8,100	922
Other debtors	50,100	1,100

	58,200	2,022

7. Creditors: Amounts Falling Due Within One Year

	2026	2025
	£	£
Trade creditors	5,437	12,077
Amounts owed to group undertakings	123,980	74,500
Other creditors	20,876	4,641
Taxation and social security	7,117	4,284

	157,410	95,502

8. Share Capital

	2026	2025
	£	£
Called Up Share Capital not Paid	100	100

Amount of Allotted, Called Up Share Capital	100	100

9. Pension Commitments

The company operates a defined contribution pension scheme for employees. The assets of the scheme are held separately from those of the company in an independently administered fund. At the balance sheet date unpaid contributions of £628 (2025: £558) were due to the fund. They are included in other creditors.

Page 5

Page 6

Multimedix Limited

Notes to the Financial Statements (continued)

For The Year Ended 31 March 2026

10. Ultimate Parent Undertaking and Controlling Party

The company's immediate and ultimate parent undertaking is Multimedix Holdings Limited . Multimedix Holdings Limited was incorporated in England & Wales and its registered office is Unit 56, Hayhill Industrial Estate, 47 Hayhill, Barrow Upon Soar, Leicestershire, LE12 8LD. Group accounts are not drawn up.

Page 6